Physician profile
Huiling Liu
NPI 1346637493
$2,763.66
in general payments reported to CMS, 2019-2025
22 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $284 · 2021: $365 · 2022: $633 · 2023: $368 · 2024: $369 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $423.14 | 2019-2024 | Xarelto |
| Pfizer INC. | $403.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $316.64 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $260.93 | 2019-2020 | |
| Abbvie INC. | $242.90 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.86 | 2019-2023 | Eliquis |
| Alexion Pharmaceuticals, INC. | $126.79 | 2022-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $122.48 | 2020-2023 | Verquvo |
| Dilon Technologies, INC. | $118.23 | 2025 | Hemoblast Bellows |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.51 | 2021-2022 | |
| Abiomed | $78.04 | 2024-2025 | Impella |
| Inari Medical, INC. | $74.47 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $59.38 | 2019-2024 | Yupelri |
| Amgen INC. | $43.84 | 2020-2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $36.82 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $32.14 | 2025 | Brukinsa |
| Medtronic, INC. | $28.16 | 2024 | Linq II |
| Vifor Pharma, INC. | $26.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.31 | 2021 | |
| Travere Therapeutics, INC. | $17.29 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.15 | 2024 | Terlivaz |
| Lexicon Pharmaceuticals, INC. | $13.80 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huiling Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.